New York, NYNCT07871435Now EnrollingIRB Ready

Metastatic Castration-resistant Prostate Cancer (mCRPC) Clinical Trial in New York, NY

Access cutting-edge metastatic castration-resistant prostate cancer (mcrpc) treatment through this phase 1/2 clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by GI Innovation, Inc.

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access metastatic castration-resistant prostate cancer (mcrpc) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metastatic castration-resistant prostate cancer (mcrpc) treatment provided free

Apply for This New York Location

Check if you qualify for this metastatic castration-resistant prostate cancer (mcrpc) clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Metastatic Castration-resistant Prostate Cancer (mCRPC) Study in New York

The purpose of this clinical trial is to evaluate the safety, tolerability, and preliminary anti-cancer activity of GI-102 in combination with pasritamig in adult men with metastatic castration-resistant prostate cancer (mCRPC) whose cancer has progressed after previous treatment with a novel hormonal therapy (NHT).

Sponsor: GI Innovation, Inc.

Who Can Participate

Inclusion Criteria

Male participants aged ≥18 years (or ≥19 years according to local regulatory requirements).
ECOG performance status of 0 to 1.
Histologically confirmed advanced prostate adenocarcinoma with measurable or evaluable disease. Adenocarcinoma with small cell or neuroendocrine (NE) features is permitted. However, primary small cell carcinoma, carcinoid tumor, mixed NE carcinoma, or large cell NE carcinoma (or pathologic evidence of conversion to) is disallowed.
Metastatic castration-resistant prostate cancer (mCRPC) with documented disease progression following at least one line of novel androgen receptor-targeted therapy.
PSA ≥2 ng/mL at screening.
No more than 2 prior taxane regimens and no prior cytotoxic chemotherapy other than taxane therapy.
Prior orchiectomy or ongoing androgen deprivation therapy with castrate testosterone levels.
Adequate organ and marrow function and adequate cardiovascular function.
Adequate recovery from prior anticancer therapy-related adverse events.
Willingness and ability to comply with study procedures and protocol-specified contraception requirements. Key

Exclusion Criteria

Active or prior CNS metastases, carcinomatous meningitis, or clinically unstable spinal cord compression.
Significant uncontrolled cardiovascular, pulmonary, hepatic, autoimmune, infectious, or other systemic disease.
Active or recent clinically significant infection, including active tuberculosis, hepatitis B, or hepatitis C.
Active pneumonitis or interstitial lung disease (ILD), or history of clinically significant pneumonitis/ILD.
Recent treatment with investigational products, prohibited immunomodulating agents, radiotherapy, major surgery, or other protocol-defined prohibited therapies.
Prior treatment with CD3-directed therapies, including KLK2-CD3 bispecific antibodies or other CD3-targeting T-cell engagers.
Known hypersensitivity to GI-102, pasritamig, or their excipients, or any other condition that may interfere with study participation or interpretation of results.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT07871435) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Castration-resistant Prostate Cancer (mCRPC) Treatment Options in New York, NY

If you're searching for metastatic castration-resistant prostate cancer (mcrpc) treatment options in New York, NY, this clinical trial (NCT07871435) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced metastatic castration-resistant prostate cancer (mcrpc) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic castration-resistant prostate cancer (mcrpc) clinical trials near you to find additional studies recruiting in your area.

More Prostate Cancer Trials in New York, NY

See all prostate cancer clinical trials recruiting in New York — not just this study.

Browse Prostate Cancer Trials in New York →

Browse More Trials by Condition

Prostate Cancer TrialsEssential Tremor TrialsRheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsRetinitis Pigmentosa TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY